Recently, Arnold et al. reported that chemotherapy plus anti-epidermal growth factor receptor (EGFR) antibody therapy was not significantly beneficial for patients with right-sided colon cancer and KRAS wild-type for overall survival and progression-free survival [23]; similar suggestions were echoed in the Japanese Society for Cancer of the Colon and Rectum guidelines 2019 for the treatment of colorectal cancer. The gene discussed is KRAS; the disease is colorectal cancer.